Japan Approves First Coronavirus Vaccine But Hurdles Ahead?
Pfizer Gets Nod But Challenges Ahead?
Japanese authorities have issued their first approval for a coronavirus vaccine, to Pfizer/BioNTech’s mRNA product Comirnaty, but public vaccine hesitancy and logistics challenges could be hurdles to achieving high administration rates and effective herd immunity.
You may also be interested in...
Three groups representing the domestic and multinational research-based pharma industry in Japan present a unified position as they call for policy changes they see as providing the right environment for investment, innovation and a sustainable healthcare system.
Takeda agreed with its contract manufacturer to grant access to its dengue vaccine production capacity for Johnson & Johnson's COVID-19 vaccine. Frontrunner Moderna started a pediatric trial in children as young as six months. GSK and Medicago began the Phase III portion of a Phase II/III vaccine trial. And China is limiting inbound travel to people vaccinated with China-made vaccines.
A roundup of the latest global developments around COVID-19, including progress in Asia for Moderna's vaccine, promising results for a Lilly antibody combo, and new vaccine support moves by CEPI.